HBM Holdings Enters Strategic Collaboration for Novel CRH Therapies

HBM Holdings Ltd. ( (HK:2142) ) has issued an update.

HBM Holdings Limited announced a license and collaboration agreement through its subsidiary, HBM Alpha Therapeutics, with a business partner to develop therapies targeting corticotropin-releasing hormone (CRH) for various disorders. The agreement grants the partner exclusive worldwide rights, excluding Greater China, to exploit pharmaceutical products containing HBM9013, with potential payments to HBMAT totaling up to $395 million and additional royalties. This collaboration could enhance HBM Holdings’ position in the biotechnology industry by addressing unmet medical needs in CRH-related disorders, potentially impacting stakeholders positively.

More about HBM Holdings Ltd.

HBM Holdings Limited is a biotechnology company focused on developing innovative therapies for rare genetic and endocrinological diseases. Its subsidiary, HBM Alpha Therapeutics, is working on antibody therapeutics targeting conditions such as congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

YTD Price Performance: 206.99%

Average Trading Volume: 6,164,455

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$4.31B

For detailed information about 2142 stock, go to TipRanks’ Stock Analysis page.